LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Latest Information Update: 13 May 2024
Price :
$35 *
At a glance
- Drugs Estradiol/norethisterone acetate/relugolix (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY EXTENSION
- Sponsors Myovant Sciences
- 18 Oct 2023 of secondary analysis assessing the efficacy and safety of relugolix combination therapy in the subgroup population of Black/African American women with uterine fibroids, published in the American Journal of Obstetrics and Gynecology
- 09 Feb 2023 This trial has been discontinued in Poland.
- 03 Nov 2022 Results of pooled analysis (NCT03049735; NCT03103087; NCT03412890) assessing the long-term efficacy and safety of relugolix combination therapy treatment for up to 52 weeks published in the Obstetrics and Gynecology